TY - JOUR AU - Fan, Chengming AU - Oduk, Yasin AU - Zhao, Meng AU - Lou, Xi AU - Tang, Yawen AU - Pretorius, Danielle AU - Valarmathi, Mani T. AU - Walcott, Gregory P. AU - Yang, Jinfu AU - Menasche, Philippe AU - Krishnamurthy, Prasanna AU - Zhu, Wuqiang AU - Zhang, Jianyi T1 - Myocardial protection by nanomaterials formulated with CHIR99021 and FGF1 PY - 2020/06/18/ AB - The mortality of patients suffering from acute myocardial infarction is linearly related to the infarct size. As regeneration of cardiomyocytes from cardiac progenitor cells is minimal in the mammalian adult heart, we have explored a new therapeutic approach, which leverages the capacity of nanomaterials to release chemicals over time to promote myocardial protection and infarct size reduction. Initial screening identified 2 chemicals, FGF1 and CHIR99021 (a Wnt1 agonist/GSK-3β antagonist), which synergistically enhance cardiomyocyte cell cycle in vitro. Poly-lactic-co-glycolic acid nanoparticles (NPs) formulated with CHIR99021 and FGF1 (CHIR + FGF1-NPs) provided an effective slow-release system for up to 4 weeks. Intramyocardial injection of CHIR + FGF1-NPs enabled myocardial protection via reducing infarct size by 20%–30% in mouse or pig models of postinfarction left ventricular (LV) remodeling. This LV structural improvement was accompanied by preservation of cardiac contractile function. Further investigation revealed that CHIR + FGF1-NPs resulted in a reduction of cardiomyocyte apoptosis and increase of angiogenesis. Thus, using a combination of chemicals and an NP-based prolonged-release system that works synergistically, this study demonstrates a potentially novel therapy for LV infarct size reduction in hearts with acute myocardial infarction. JF - JCI Insight JA - JCI Insight SN - 2379-3708 DO - 10.1172/jci.insight.132796 VL - 5 IS - 12 UR - https://doi.org/10.1172/jci.insight.132796 PB - The American Society for Clinical Investigation ER -